热门资讯> 正文

Passage Bio GAAP每股收益为-4.09美元

2026-03-04 04:03

Passage BIO(PASG) 0

Passage Bio press release (PASG): Q4 GAAP EPS of -$4.09.
Cash and cash equivalents were $46.3 million as of December 31, 2025, as compared to cash, cash equivalents, and marketable securities of $76.8 million as of December 31, 2024. The company expects current cash and cash equivalents to fund operations through 1Q 2027.

More on Passage Bio

Seeking Alpha’s Quant Rating on Passage Bio
Historical earnings data for Passage Bio
Financial information for Passage Bio

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。